These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 31648843)

  • 1. Cognitive enhancement in schizophrenia by buspirone: Role of serotonin
    Sumiyoshi T
    Schizophr Res; 2020 Jan; 215():455-456. PubMed ID: 31648843
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study.
    Sumiyoshi T; Park S; Jayathilake K; Roy A; Ertugrul A; Meltzer HY
    Schizophr Res; 2007 Sep; 95(1-3):158-68. PubMed ID: 17628435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-treatment of buspirone with atypical antipsychotic drugs (AAPDs) improved neurocognitive function in chronic schizophrenia.
    Wang Y; Yang X; Song X; Zhao L; Wei J; Wang J; Tian H; Zheng C; Wei M; Wang Q; Guo W; Deng W; Li T; Ma X
    Schizophr Res; 2019 Jul; 209():135-140. PubMed ID: 31101513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunctive azapirone for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials.
    Zheng W; Li XH; Cai DB; Yang XH; Ungvari GS; Ng CH; Ning YP; Xiang YT
    Eur Neuropsychopharmacol; 2018 Jan; 28(1):149-158. PubMed ID: 29174529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist.
    Piskulić D; Olver JS; Maruff P; Norman TR
    Hum Psychopharmacol; 2009 Aug; 24(6):437-46. PubMed ID: 19637398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia.
    Ghaleiha A; Noorbala AA; Farnaghi F; Hajiazim M; Akhondzadeh S
    J Clin Psychopharmacol; 2010 Dec; 30(6):678-82. PubMed ID: 21105281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open study of buspirone augmentation of neuroleptics in patients with schizophrenia.
    Sirota P; Epstein B; Benatov R; Sousnostzky M; Kindler S
    J Clin Psychopharmacol; 2001 Aug; 21(4):454-5. PubMed ID: 11476132
    [No Abstract]   [Full Text] [Related]  

  • 8. Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics.
    Sumiyoshi T; Bubenikova-Valesova V; Horacek J; Bert B
    Adv Ther; 2008 Oct; 25(10):1037-56. PubMed ID: 18839076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching patients from olanzapine or risperidone to a combination treatment using perphenazine plus buspirone: evaluation of antipsychotic efficacy and side-effects, including extrapyramidal effects and weight loss.
    Andersen TH; Bech P; Larsen NE
    Nord J Psychiatry; 2005; 59(3):205-8. PubMed ID: 16195121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: a meta-analysis.
    Kishi T; Meltzer HY; Iwata N
    Int J Neuropsychopharmacol; 2013 Jul; 16(6):1259-66. PubMed ID: 23551924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?
    Meltzer HY; Sumiyoshi T
    Behav Brain Res; 2008 Dec; 195(1):98-102. PubMed ID: 18707769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonergic agents in the treatment of acute neuroleptic-induced akathisia: open-label study of buspirone and mianserin.
    Poyurovsky M; Weizman A
    Int Clin Psychopharmacol; 1997 Sep; 12(5):263-8. PubMed ID: 9466160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Augmentation with buspirone: a review.
    Harvey KV; Balon R
    Ann Clin Psychiatry; 1995 Sep; 7(3):143-7. PubMed ID: 8646275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia.
    Meltzer HY; Massey BW; Horiguchi M
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1572-86. PubMed ID: 22283753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsychotic medication: the potential role of 5-HT(1A) receptor agonism.
    McCreary AC; Jones CA
    Curr Pharm Des; 2010; 16(5):516-21. PubMed ID: 19909230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving cognition in schizophrenia with antipsychotics that elicit neurogenesis through 5-HT(1A) receptor activation.
    Schreiber R; Newman-Tancredi A
    Neurobiol Learn Mem; 2014 Apr; 110():72-80. PubMed ID: 24423786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Trends in the Treatment of Schizophrenia.
    Meltzer HY
    CNS Neurol Disord Drug Targets; 2017; 16(8):900-906. PubMed ID: 28758583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of buspirone in the treatment of schizophrenia.
    Sovner R; Parnell-Sovner N
    J Clin Psychopharmacol; 1989 Feb; 9(1):61-2. PubMed ID: 2708556
    [No Abstract]   [Full Text] [Related]  

  • 19. The neurobiology of cognition in schizophrenia.
    Tamminga CA
    J Clin Psychiatry; 2006 Sep; 67(9):e11. PubMed ID: 17081078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives.
    Newman-Tancredi A
    Curr Opin Investig Drugs; 2010 Jul; 11(7):802-12. PubMed ID: 20571976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.